Ivabradine
Other Cardiac Preparations
Sold as Corlentor · Procoralan · LANCORA
- Drug class
- Other Cardiac Preparations
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 55
Overview
Ivabradine is an active pharmaceutical ingredient in the Other Cardiac Preparations group (C01EB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 48 | May 22, 2026 |
| EU European Union | EMA | 5 | November 17, 2025 |
| CA Canada | Health Canada | 2 | June 26, 2025 |
GBUnited Kingdom· MHRA
48 products
Uses
Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. Ivabradine is indicated: - in adults unable to tolerate or with a contra-indication to the use of beta-blockers - or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.
Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.
1)
EUEuropean Union· EMA
5 products
Uses
Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. Ivabradine is indicated: - in adults unable to tolerate or with a contraindication to the use of beta-blockers - or in combination with beta-blockers in patients inadequately controlled with an optimal beta- blocker dose.
1).
How to take
CACanada· Health Canada
2 products
Uses
, 4 DOSAGE AND ADMINISTRATION and 10 CLINICAL PHARMACOLOGY). 4. Geriatrics ( 75 years of age) LANCORA® has only been studied in a limited number of patients 75 years of age and older. The SHIFT trial showed a higher risk of bradycardia among patients aged ≥ 75 years treated with LANCORA®, at a starting dose of 5 mg bid.
9% in the placebo group for the overall study population. A lower starting dose is therefore recommended in these patients (see 14 CLINICAL TRIALS and 4 DOSAGE AND ADMINISTRATION). 5. Hepatic impairment Caution should be exercised when using LANCORA® in patients with moderate hepatic impairment.
The use of LANCORA® in patients with severe hepatic impairment is contraindicated since it has not been studied in this population and a large increase in systemic exposure is expected (see
Drug interactions
Known interactions involving Ivabradine. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 337. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL172770365 · revised December 20, 2024
- [2]European Medicines Agency · EMEA/H/C/004187 · revised November 17, 2025
- [3]Health Canada (DPD) · 02459973 · revised June 26, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.